LOTTE BIOLOGICS to Showcase at

CPHI Worldwide 2025 in Frankfurt

▲ [Fig1.] LOTTE BIOLOGICS’ exclusive booth at CPHI 2025

■ Showcasing dual-site (Syracuse–Songdo) strengths and proven quality assurance

LOTTE BIOLOGICS (CEO James Park) announced its participation in CPHI 2025, held in Frankfurt, Germany from October 28–30. CPHI 2025 is expected to bring together more than 2,400 companies and over 60,000 attendees from around the world.

On Day 1, Kern Chang, Chief Technical Officer of LOTTE BIOLOGICS, will speak in an ADC seminar. His presentation, titled “Accelerating Bioconjugate Development and Manufacturing with LOTTE BIOLOGICS’ ADC Platform,” will outline the company’s capabilities and operational readiness for ADC development and manufacturing.

At the LOTTE BIOLOGICS booth, Joon Chang, Chief Business Officer of LOTTE BIOLOGICS, will deliver in-booth presentations highlighting the strategic advantages of the company’s dual-site model—the Syracuse Bio Campus (U.S.) and the Songdo site (Korea)—and its proven quality systems. On Day 2, Kern Chang will return for an additional in-booth session to discuss the company’s differentiated competitiveness as a global ADC CDMO. 

To expand on-site engagement, LOTTE BIOLOGICS will host light booth activities, including an Event Zone and Happy Hour during select in-booth presentation times, offering visitors an opportunity to connect in a relaxed setting.

Grounded in its dual-site footprint and verified quality assurance, LOTTE BIOLOGICS aims to further strengthen its position as a global CDMO partner. The company also seeks to support customers responding to evolving supply-chain dynamics, including reshoring trends in key markets.

James Park, CEO of LOTTE BIOLOGICS, said, “We continue to enhance our role as an agile, innovation-driven partner that can respond quickly to market needs. Beyond this exhibition, we will actively pursue partnerships through upcoming global industry events, further reinforcing our global competitiveness.”